Semi-Annual Consolidated Statement Of Cash Flows

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7302029

Concept As at
2024-09-30
2024-04-01 to
2024-09-30
As at
2024-03-31
As at
2023-09-30
2023-04-01 to
2023-09-30
As at
2023-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
3,418,000,000 JPY
3,703,000,000 JPY
Interest and dividends received
146,000,000 JPY
189,000,000 JPY
Interest paid
-22,000,000 JPY
-21,000,000 JPY
Income taxes paid
-2,381,000,000 JPY
-774,000,000 JPY
Net cash provided by (used in) operating activities
1,159,000,000 JPY
3,097,000,000 JPY
Cash flows from investing activities
Purchase of securities
JPY
-500,000,000 JPY
Purchase of property, plant and equipment
-1,560,000,000 JPY
-639,000,000 JPY
Purchase of investment securities
JPY
-299,000,000 JPY
Proceeds from sale of investment securities
JPY
2,883,000,000 JPY
Other, net
-303,000,000 JPY
-14,000,000 JPY
Net cash provided by (used in) investing activities
-1,783,000,000 JPY
1,382,000,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-1,840,000,000 JPY
-2,298,000,000 JPY
Dividends paid
-566,000,000 JPY
-226,000,000 JPY
Net cash provided by (used in) financing activities
-2,406,000,000 JPY
-2,539,000,000 JPY
Other, net
JPY
-24,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
-3,000,000 JPY
0 JPY
Net increase (decrease) in cash and cash equivalents
-3,033,000,000 JPY
1,940,000,000 JPY
Cash and cash equivalents
13,705,000,000 JPY
16,738,000,000 JPY
19,446,000,000 JPY
17,505,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.